<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector — Live Feed</title><link>https://www.live-feeds.com/feed/fda-rejects-cancer-drug-invented-in-china-in-blow-to-beijing-s-biotech-sector</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/fda-rejects-cancer-drug-invented-in-china-in-blow-to-beijing-s-biotech-sector/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>FDA Rejects Summit Lung Cancer Drug Ivonescimab</title><link>https://www.live-feeds.com/feed/fda-rejects-cancer-drug-invented-in-china-in-blow-to-beijing-s-biotech-sector</link><guid isPermaLink="false">https://www.live-feeds.com/feed/fda-rejects-cancer-drug-invented-in-china-in-blow-to-beijing-s-biotech-sector#u209760</guid><pubDate>Fri, 20 Nov 2026 04:15:18 +0000</pubDate><description>The US Food and Drug Administration has declined to approve ivonescimab, a lung cancer treatment from Summit Therapeutics that was invented in China, dealing a significant setback to Beijing&amp;#039;s broader biotechnology sector. The regulatory rejection derails the American market arrival of the much-hyped PD-1xVEGF drug class after a clinical trial missed a key survival goal. Summit Therapeutics provided an update regarding the Biologics License Application following the decision, while the company&amp;#039;s stock plunged overnight in response to the news.Why it mattersThe rejection places the en</description></item>
</channel></rss>